糖尿病视网膜病变治疗护理中使用的计费代码准确性
这项回顾性病历审查在3个临床机构(1个学术机构和2个私人机构)进行,纳入2011至2013年间就诊的146例糖尿病视网膜病变患者,对每位患者2年内每次就诊分别审查计费数据和病历数据,评估诊断、操作和治疗计费代码的阳性预测值和阴性预测值。结果显示多数常用代码的阳性预测值为89.5%至100%、阴性预测值为88.6%至100%,仅B型超声和眼球筋膜下注射的准确性存疑。
要点
- 多数常用计费代码的阳性预测值为89.5%至100%,阴性预测值为88.6%至100%。
- 不常用的阿柏西普、曲安奈德和地塞米松植入物代码阳性预测值均为100%,阴性预测值为99.7%至100%。
- B型超声阳性预测值为69.6%,眼球筋膜下注射灵敏度仅40%,准确性存疑。
核心结论
- 数据提示,来自保险计费索赔的诊断、操作和治疗代码能准确反映糖尿病视网膜病变患者的病历记录。
研究设计与样本
- 回顾性病历审查,在3个临床机构(1个学术机构和2个私人机构)进行,纳入2011至2013年间就诊的146例糖尿病视网膜病变患者,由11名医生诊治,共审查2个日历年的1072次就诊。
- 每位患者2年内的每次就诊均审查两次,一次审查计费数据,另一次审查病历数据。
- 数据收集与分析时间为2015年10月至2016年7月。
主要发现
- 患者平均年龄60.3岁(标准差12.5),女性占49.3%(n=72),白人占48.6%(n=71),黑人占37.0%(n=54),1型糖尿病占18.5%(n=27),平均血红蛋白A1C水平为7.7%(标准差1.8)。
- 使用频繁且阳性预测值(范围89.5%至100%)和阴性预测值(88.6%至100%)均高的代码包括玻璃体腔内注射、局灶激光、全视网膜光凝、手术侧别、雷珠单抗、贝伐珠单抗、眼底照相、荧光素血管造影和光学相干断层扫描。
- 使用不频繁(少于20次)但阳性预测值(均为100%)和阴性预测值(99.7%至100%)仍高的代码为阿柏西普、曲安奈德和地塞米松植入物。
- 不常用的B型超声(阳性预测值69.6%)和眼球筋膜下注射(阳性预测值100%;阴性预测值99.7%,但灵敏度仅40%)的代码准确性存疑。
- 除眼球筋膜下注射(40%)外,所有代码的灵敏度高(范围87.6%至100%),特异度高(范围97.2%至100%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Insurance billing claim databases represent a growing field of scientific inquiry within ophthalmology. Validating the accuracy of billing claim codes used during the care of diabetic retinopathy is a necessary precursor to fully understanding the underlying data and subsequent results of these types of studies. OBJECTIVE: To determine the accuracy of diagnostic, procedural, and therapeutic billing codes used in the treatment of diabetic retinopathy. DESIGN, SETTING, AND PARTICIPANTS: This retrospective medical record review was conducted at 3 clinical practices (1 academic and 2 private). Insured patients with diabetic retinopathy were seen by the practices between 2011 and 2013. Each patient then had every visit for 2 years reviewed twice, once for billing data and the second for data from the medical record. Data were collected and analyzed from October 2015 to July 2016. MAIN OUTCOMES AND MEASURES: The positive predictive value (PPV) and negative predictive value (NPV) for each code of interest. Sensitivity and specificity were secondary outcomes. RESULTS: A total of 146 patients (mean [SD] age, 60.3 [12.5] years) from 11 physicians had 1072 encounters reviewed over 2 calendar years. Among the included patients, 49.3% were female (n = 72), 48.6% were white (n = 71), 37.0% were black (n = 54), and 18.5% had type 1 diabetes and a mean (SD) hemoglobin A1C level of 7.7% (1.8) (n = 27). Nearly all codes of interest that were used frequently also had a high PPV (range, 89.5%-100%) and NPV (88.6%-100%) including billing codes for intravitreal injection, focal laser, panretinal photocoagulation, laterality of procedure, ranibizumab, bevacizumab, fundus photographs, fluorescein angiography, and optical coherence tomography. Codes that were used infrequently (<20 instances) but still had a high PPV (all 100%) and NPV (99.7%-100%) were codes for aflibercept, triamcinolone, and the dexamethasone implant. Only the codes for infrequently used B-scan ultrasonography (PPV, 69.6%) and subtenon injection (PPV, 100%; NPV, 99.7%, but sensitivity of only 40%) were found to be of questionable accuracy. Other than subtenon injection (40%), all codes were also found to have a high sensitivity (range, 87.6%-100%) and a high specificity (range, 97.2%-100%). CONCLUSIONS AND RELEVANCE: These data suggest diagnostic, procedure, and therapeutic codes derived from insurance billing claims accurately reflect the medical record for patients with diabetic retinopathy.
引用
- Lau M, Prenner JL, Brucker AJ, et al. Accuracy of Billing Codes Used in the Therapeutic Care of Diabetic Retinopathy. JAMA Ophthalmol. 2017. PMID: 28570735. doi:10.1001/jamaophthalmol.2017.1595
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。